Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 31 (November 1), 2005: pp. 8033-8040
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.9661
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kindler, H. L.
Right arrow Articles by Vokes, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kindler, H. L.
Right arrow Articles by Vokes, E. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Hedy L. Kindler, Gregory Friberg, Deepti A. Singh, Gershon Locker, Sreenivasa Nattam, Mark Kozloff, David A. Taber, Theodore Karrison, Abraham Dachman, Walter M. Stadler, Everett E. Vokes

From the Section of Hematology/Oncology, University of Chicago Medical Center; Cancer Research Center; Department of Health Studies; Department of Radiology, University of Chicago, Chicago; Evanston Hospital, Evanston; Ingalls Hospital, Harvey, IL; Fort Wayne Medical Center, Fort Wayne; and Northern Indiana Cancer Research Consortium, South Bend, IN

Address reprint requests to Hedy Lee Kindler, MD, University of Chicago Medical Center, Section of Hematology/Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637-1470; e-mail: hkindler{at}medicine.bsd.uchicago.edu

PURPOSE: Vascular endothelial growth factor (VEGF) plays a key role in the biology and prognosis of pancreatic cancer. Inhibitors of VEGF suppress the growth of pancreatic cancer in preclinical models. The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab.

PATIENTS AND METHODS: Patients with previously untreated advanced pancreatic cancer received gemcitabine 1,000 mg/m2 intravenously over 30 minutes on days 1, 8, and 15 every 28 days. Bevacizumab, 10 mg/kg, was administered after gemcitabine on days 1 and 15. Tumor measurements were assessed every two cycles. Plasma VEGF levels were obtained pretreatment.

RESULTS: Fifty-two patients were enrolled at seven centers between November 2001 and March 2004. All patients had metastatic disease, and 83% had liver metastases. Eleven patients (21%) had confirmed partial responses, and 24 (46%) had stable disease. The 6-month survival rate was 77%. Median survival was 8.8 months; median progression-free survival was 5.4 months. Pretreatment plasma VEGF levels did not correlate with outcome. Grade 3 and 4 toxicities included hypertension in 19% of the patients, thrombosis in 13%, visceral perforation in 8%, and bleeding in 2%.

CONCLUSION: The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients. Additional study is warranted. A randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo is ongoing in the Cancer and Leukemia Group B.

Supported by National Cancer Institute Grant No. N01-CM-17102.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL; 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA; and the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, January 22-24, 2004, San Francisco, CA.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in Medical OncologyHome page
J. S.W. Lind and E. F. Smit
Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 95 - 107.
[Abstract] [PDF]

Home page
 JCOHome page
C. H. Crane, K. Winter, W. F. Regine, H. Safran, T. A. Rich, W. Curran, R. A. Wolff, and C. G. Willett
Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
J. Clin. Oncol., September 1, 2009; 27(25): 4096 - 4102.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Poplin, Y. Feng, J. Berlin, M. L. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'Dwyer, D. Haller, P. Catalano, et al.
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol., August 10, 2009; 27(23): 3778 - 3785.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Matsubara, M. Ono, A. Negishi, H. Ueno, T. Okusaka, J. Furuse, K. Furuta, E. Sugiyama, Y. Saito, N. Kaniwa, et al.
Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine
J. Clin. Oncol., May 1, 2009; 27(13): 2261 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al.
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
Y.-Y. SHAO, Z.-Z. LIN, P.-C. LIANG, Y.-W. TIEN, and A.-L. CHENG
Gastric Perforation Presenting as Empyema in a Patient with Pancreatic Cancer on Bevacizumab Treatment
Anticancer Res, May 1, 2009; 29(5): 1665 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
H. Seeliger, P. Camaj, I. Ischenko, A. Kleespies, E. N. De Toni, S. E. Thieme, H. Blum, G. Assmann, K.-W. Jauch, and C. J. Bruns
EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma
Mol. Cancer Res., February 1, 2009; 7(2): 189 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. D. Norden, J. Drappatz, A. S. Ciampa, L. Doherty, D. C. LaFrankie, S. Kesari, and P. Y. Wen
Colon perforation during antiangiogenic therapy for malignant glioma
Neuro-oncol, January 1, 2009; 11(1): 92 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Tawada, T. Ishihara, A. Kobayashi, T. Yamaguchi, T. Tsuyuguchi, M. Matsuyama, and O. Yokosuka
Quantitative Analysis of Vascular Endothelial Growth Factor in Liver Metastases from Pancreatic Carcinoma as a Predictor of Chemotherapeutic Effect and Prognosis
Clin. Cancer Res., November 15, 2008; 14(22): 7438 - 7443.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull., September 1, 2008; 87(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Ghaneh, E Costello, and J P Neoptolemos
Biology and management of pancreatic cancer
Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol, August 1, 2008; 10(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Small Jr, J. Berlin, G. M. Freedman, A. A. Konski, T. S. Lawrence, M. S. Talamonti, M. F. Mulcahy, A. B. Chakravarthy, M. M. Zalupski, P. A. Philip, et al.
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3100 - 3101.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. Nieto, M. L. Grossbard, and P. Kozuch
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Oncologist, May 1, 2008; 13(5): 562 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Cao, M. Bloomston, T. Zhang, W. L. Frankel, G. Jia, B. Wang, N. C. Hall, R. M. Koch, H. Cheng, M. V. Knopp, et al.
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
Clin. Cancer Res., March 15, 2008; 14(6): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky
Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials
J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. D. Badgwell, E. R. Camp, B. Feig, R. A. Wolff, C. Eng, L. M. Ellis, and J. N. Cormier
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Ann. Onc., March 1, 2008; 19(3): 577 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Zhang, A. Hamza, X. Cao, B. Wang, S. Yu, C.-G. Zhan, and D. Sun
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Mol. Cancer Ther., January 1, 2008; 7(1): 162 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. C. Bendell
Latest Data on the Treatment of Upper Gastrointestinal Cancers
ASCO Educational Book, January 1, 2008; 2008(1): 184 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. C. DeRosier, S. M. Vickers, K. R. Zinn, Z. Huang, W. Wang, W. E. Grizzle, J. Sellers, C. R. Stockard Jr., T. Zhou, P. G. Oliver, et al.
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
Mol. Cancer Ther., December 1, 2007; 6(12): 3198 - 3207.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P. Ghaneh, E. Costello, and J. P Neoptolemos
Biology and management of pancreatic cancer
Gut, August 1, 2007; 56(8): 1134 - 1152.
[Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. J. Mistry, A. Bank, and G. F. Atweh
Synergistic Antiangiogenic Effects of Stathmin Inhibition and Taxol Exposure
Mol. Cancer Res., August 1, 2007; 5(8): 773 - 782.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. Toutouzas, J. Karabelas, S. Vaina, and C. Stefanadis
Antivascular Endothelial Growth Factor-A Treatment: New Perspectives for High-Risk Plaque Stabilization
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 186 - 186.
[Full Text] [PDF]

Home page
 JCOHome page
S. A. Welch and M. J. Moore
Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?
J. Clin. Oncol., June 1, 2007; 25(16): 2159 - 2161.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, et al.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., May 20, 2007; 25(15): 1960 - 1966.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. R. Alberts, G. J. Gores, G. P. Kim, L. R. Roberts, M. L. Kendrick, C. B. Rosen, S. T. Chari, and J. A. Martenson
Treatment Options for Hepatobiliary and Pancreatic Cancer
Mayo Clin. Proc., May 1, 2007; 82(5): 628 - 637.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Mahadevan and D. D. Von Hoff
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Taieb, T Lecomte, T Aparicio, A Asnacios, T Mansourbakht, P Artru, D Fallik, J. Spano, B Landi, G Lledo, et al.
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
Ann. Onc., March 1, 2007; 18(3): 498 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar
Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications
Am. J. Pathol., January 1, 2007; 170(1): 1 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. F. Yang, R. T.P. Poon, Y. Liu, C. K. Lau, D. W. Ho, K. H. Tam, C. T. Lam, and S. T. Fan
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
Mol. Cancer Ther., September 1, 2006; 5(9): 2261 - 2270.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Mol. Cancer Ther., August 1, 2006; 5(8): 1950 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. R. Cardenes, E. G. Chiorean, J. DeWitt, M. Schmidt, and P. Loehrer
Locally advanced pancreatic cancer: current therapeutic approach.
Oncologist, June 1, 2006; 11(6): 612 - 623.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. S. Kerbel
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Science, May 26, 2006; 312(5777): 1171 - 1175.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online